At this stage, it is difficult to conclude which of the BA6b9-dependent effects (i.e. AERP prolongation, inhibition of atrial inflammation/fibrosis, and attenuation of Cx43 lateralization) contribute to the potent AF substrate inhibition mediated by this treatment. The gene discussed is GJA1; the disease is atrial fibrillation.